Search Results - "Gadgeel, S.M."

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma by Krug, A.K., Enderle, D., Karlovich, C., Priewasser, T., Bentink, S., Spiel, A., Brinkmann, K., Emenegger, J., Grimm, D.G., Castellanos-Rizaldos, E., Goldman, J.W., Sequist, L.V., Soria, J.-C., Camidge, D.R., Gadgeel, S.M., Wakelee, H.A., Raponi, M., Noerholm, M., Skog, J.

“…A major limitation of circulating tumor DNA (ctDNA) for somatic mutation detection has been the low level of ctDNA found in a subset of cancer patients. We…”
Get full text

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407 by Paz-Ares, L., Langer, C.J., Novello, S., Halmos, B., Cheng, Y., Gadgeel, S.M., Hui, R., Sugawara, S., Borghaei, H., Cristescu, R., Aurora-Garg, D., Albright, A., Loboda, A., Kobie, J., Lunceford, J., Ayers, M., Lubiniecki, G.M., Pietanza, M.C., Piperdi, B., Garassino, M.C.

Get full text

Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders by Gadgeel, S.M, Soria, J.C, Felip, E, Cobo, M, Lu, S, Syrigos, K, Lee, K.H, Göker, E, Georgoulias, V, Li, W, Guclu, S, Isla, D, Ardizzoni, A, Dupuis, N, Gibson, N, Krämer, N, Bühnemann, C, Solca, F, Ehrnrooth, E, Goss, G

Get full text

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer by Soria, J, Sequist, L.V, Goldman, J.W, Wakelee, H.A, Gadgeel, S.M, Varga, A, Yu, H.A, Solomon, B.J, Ou, S.H, Papadimitrakopoulou, V, Oxnard, G.R, Horn, L, Dziadziuszko, R, Chao, B, Spira, A.I, Liu, S, Mekhail, T, Matheny, S, Litten, J, Camidge, R.D

Get full text

Differential Role of Soy Isoflavones in Radiotherapy of Lung Cancer: Augmenting Tumor Response and Protecting Normal Tissue by Hillman, G.G, Singh-Gupta, V, Runyan, L, Sethi, S, Yunker, C.K, Sarkar, F.H, Miller, S, Gadgeel, S.M, Joiner, M.C, Konski, A.A

Get full text

Fast Neutron Radiotherapy for Advanced Stage Non-small Cell Lung Cancer by Kollar, L.E, Chen, G.G, Paximadis, P, Joiner, M, Burmeister, J, Gadgeel, S.M, Wozniak, A.J, Baciewicz, F, Konski, A

Get full text

Salvage Fast Neutron Radiotherapy for Treatment of Refractory Non-small Cell Lung Cancer by Chen, G.G, Kollar, L, Paximadis, P, Joiner, M, Burmeister, J, Gadgeel, S.M, Wozniak, A.J, Baciewicz, F, Konski, A

Get full text

1544P Pre-treatment CT radiomics predicts survival in chemo-immunotherapy-treated small cell lung cancer by Bae, J., Prasanna, P., Gadgeel, S.M.

Get full text

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study by Mok, T., Camidge, D.R., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H.I., Ahn, J.S., Shaw, A.T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé, J., Peters, S.

“…•Investigator-assessed PFS data in the ALEX study are now mature (53% of events in the alectinib arm).•Alectinib significantly prolonged PFS vs crizotinib…”
Get full text

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib by Schoenfeld, A.J., Arbour, K.C., Rizvi, H., Iqbal, A.N., Gadgeel, S.M., Girshman, J., Kris, M.G., Riely, G.J., Yu, H.A., Hellmann, M.D.

“…Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor…”
Get full text

397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC) by Yasenchak, C, Nackaerts, K, Awada, A, Gadgeel, S.M, Hellerstedt, B, Perry, M.C, Richards, D, Yang, C.H, Scheffold, C, Lara, P.N

Get full text

1317P Renal toxicity in black patients with non-squamous non-small cell lung cancer treated with combination platinum-pemetrexed-pembrolizumab therapy by Balanchivadze, N., Nasser, Z., Shahid, M., Mckay, C., Li, P., Sohaney, R., Gadgeel, S.M.

Get full text

1388P Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC) by Gadgeel, S.M., Zhang, Q., Lin, H., Fajardo, O., Trinh, H., Arndorfer, S., Kong, S., Rahman, A., Li, S., Archer, V.R., Gainor, J.F.

Get full text

The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes by Ohri, N., Jolly, S., Cooper, B., Kabarriti, R., Bodner, W.R., Guha, C., Viswanathan, S., Shum, E., Sabari, J.K., Cheng, H., Gucalp, R., Castellucci, E., Qin, A., Gadgeel, S.M., Halmos, B.

“…Initial reports from the Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT) indicated that patients with high PD-L1 expression…”
Get full text

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT) by Ohri, N., Jolly, S., Cooper, B.T., Kabarriti, R., III, W. R. Bodner, Klein, J., Viswanathan, S., Kaufman, R., Shum, E., Sabari, J.K., Cheng, H., Gucalp, R., Castellucci, E., Qin, A., Gadgeel, S.M., Halmos, B.

Get full text

1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC) by Gadgeel, S.M., Al-Mondhiry, J., Ahn, M-J., Kim, S-W., Paz-Ares, L., Prenen, H., Boyer, M., Bustamante Alvarez, J.G., Solomon, B., Huang, S., Minocha, M., Kistler, M., Hashemi Sadraei, N.

Get full text

984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD) by Gadgeel, S.M., Gainor, J., Cappuzzo, F., Garralda, E., Lee, D.H., Mazieres, J., Kim, D-W., Zhu, V., Lopes, G., Miller, S., Nowicka, M., Trinh, H., Arndorfer, S.M., Rahman, A., Noe, J., Zhang, Q., Subbiah, V.

Get full text

1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A by Gadgeel, S.M., Mok, T.S.K., Peters, S., Nadal, E., Han, J-Y., Alatorre Alexander, J.A., Leighl, N., Sriuranpong, V., Pérol, M., Castro, G.D., de Marinis, F., Tan, D.S.W., Paul, S., Assaf, Z.J., MacLennan, M., Lohmann, T.O., Slade, M., Mathisen, M.S., Bhagawati-Prasad, V., Dziadziuszko, R.

Get full text

1307P Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world data (RWD) by Dziadziuszko, R., Zhang, Q., Li, X., Paul, S.M., Sugidono, M., Mocci, S., Kinkolykh, A., Shames, D.S., Archer, V., Mathisen, M.S., Jin, D.X., Gadgeel, S.M., Peters, S., Mok, T.

Get full text

1271P 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC by Mazieres, J., Rittmeyer, A., Gadgeel, S.M., Hida, T., Gandara, D., Cortinovis, D., Barlesi, F., Yu, W., Matheny, C., Ballinger, M., Park, K.

Get full text